ESR1 and neoplasm: We tested the effect of four clinicopathological parameters (ER status, PR status, HER2 status, or tumor stage (I–IV)) on DFNA5 methylation or expression, both on microarray and RNA-seq data, by fitting a linear mixed model (Table 1).